Month: February 2026

JENA, Germany, Feb. 26, 2026 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Leerink Partners Global Healthcare Conference. Details are as follows: Leerink Partners Global Healthcare ConferenceMarch 8 – 11, 2026 in Miami, FLFireside chat on March 9 at 9:20 AM ET InflaRx will also conduct one-on-one investor meetings on March 9th. A link to view the fireside chat live stream and its replay is available here. About InflaRxInflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation...

COLUMBUS, Ohio, Feb. 26, 2026 (GLOBE NEWSWIRE) — Bread Financial Holdings, Inc. (NYSE: BFH) (“Bread Financial” or the “Company”) today announced that its Board of Directors (the “Board”) has approved a $600 million increase to the Company’s existing share repurchase authorization. As of December 31, 2025, the Company had $240 million remaining on its open share repurchase authorization. The Company made an additional $75 million of repurchases to-date during 2026, meaning that $165 million of share repurchase capacity was available prior to today’s announcement. After today’s announcement, the Company’s share repurchase authorization is currently $765 million. There is no expiration date for the share repurchase authorization. “Today’s announcement continues to underscore our ability to execute all of our capital and growth priorities...

Giant Containers to design and build critical infrastructure and community amenities for transformative urban state park spanning northern New Jersey CONROE, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) — via IBN — Olenox Industries Inc. (NASDAQ: OLOX) (“Olenox Industries” or the “Company”) today announced that its subsidiary, Giant Containers, has been selected to provide design and construction services for critical infrastructure and amenities as part of the nearly one-mile Newark segment of New Jersey’s newest state park. The park is envisioned to be a nine-mile greenway and multi-use corridor connecting eight communities in Essex and Hudson counties in northeastern New Jersey. The initiative envisions repurposing a long-abandoned railroad right of way into a linear state park traversing the New Jersey Meadowlands, spanning the Hackensack...

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 5, 2026, before the U.S. financial markets open. Kura’s management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the financial results and provide a corporate update. The live webcast and archived replay of the event may be accessed on the Investors section of the Company’s website at www.kuraoncology.com. About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates...

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 2025 financial results on Thursday, March 5, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months. About AltimmuneAltimmune is a late clinical-stage biopharmaceutical...

Figure 1MD Projects-Eeyou Istchee James BayFigure 2Caniaspic Au 2025 ResultsFigure 3Caniapisc Au Planned IPFigure 4Samples 2025Figure 5Samples 2025Figure 6Samples 2025MONTREAL, Feb. 26, 2026 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to announce the start of an induced polarization ground (“IP’) geophysical survey on its Caniapisc Au project, in the Eeyou Istchee James Bay and Caniapiscau regions. The Caniapisc Au project is wholly owned by Midland and consists of 315 exclusive exploration rights (“EER”) covering an area of 159 square kilometres. Highlights:The 2025 exploration programs successfully identified several gold-bearing boulders, with a maximum value of 24.5 g/t Au on a selected boulder grab sample (see press release by Midland...

HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on March 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website.  About Harvard Bioscience  Harvard Bioscience, Inc. is...

TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the timing of its Premarket Approval (“PMA”) submission to the U.S. Food and Drug Administration (“FDA”) for its hemoadsorption device to treat endotoxic septic shock. Following recent interaction with the FDA, the Company now expects to submit its PMA around the end of April to mid-May 2026, compared to its previously disclosed target of Q1 2026. The updated timing reflects ongoing FDA feedback to incorporate complete 12-month mortality data from the Tigris study into the PMA submission, as well as the completion of certain non-clinical module items, including human factors engineering testing, to support...